글로벌 혈액 악성종양 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안 혈액 악성 종양 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. Globocan 2020 정보 시트에 따르면 전 세계적으로 19,292,789건의 새로운 암 사례가 확인되었고, 약 9,958,133건의 암 관련 사망자가 발생했습니다. 또한 국제암연구소(IARC)는 2040년까지 전 세계 암 발생률이 2,750만 건의 새로운 사례와 1,630만 건의 사망자로 증가할 것으로 예측합니다. 혈액 악성 종양은 종종 혈액암이라고도 하며 전 세계적으로 점점 더 흔해지고 있습니다. 미국 국립암연구소에 따르면 혈액암은 전 세계적으로 5번째로 흔한 암이며 미국에서는 암 사망의 두 번째 원인입니다. 연구자들은 향후 몇 년 동안 혈액 악성 종양의 발생률이 더욱 증가하여 치료에 대한 수요가 증가할 것으로 예상하며, 이는 혈액 악성 종양 시장에 상당한 영향을 미칠 것입니다.

Data Bridge Market Research는 혈액 악성 종양 시장이 2021년에 594억 5천만 달러 규모였으며 2029년까지 1,389억 9천만 달러에 도달할 것으로 예상되며 2022년에서 2029년까지의 예측 기간 동안 11.20%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

림프종, 백혈병, 다발성 골수종과 같은 혈액 생성 세포의 암은 혈액 악성 종양이라고 합니다. 혈소판, 적혈구(RBC) 및 백혈구(WBC)는 모두 골수의 조혈 줄기 세포와 전구 세포에서 발생하며 산소 운반, 상처 응고 및 면역 보호를 담당합니다. 현미경 , 세포 유전학, 면역 표현형 검사, 유세포 분석, 형광 원위 교잡법(FISH), 중합효소 연쇄 반응(PCR) 및 유전자 발현 프로파일링은 모두 혈액 악성 종양을 진단하는 데 사용됩니다.

보고 범위 및 시장 세분화

혈액 악성종양 시장 동향

운전자

• 혈액암의 유병률 증가

혈액암의 유병률 증가는 혈액암 시장의 성장률을 높일 것으로 추정됩니다. 혈액암은 점점 더 흔해지고 있으며, 사람들은 이 질병의 위험성을 더 일찍 알게 되었습니다. 이것이 시장을 움직이는 주요 원동력입니다. 백혈병 및 림프종 학회에 따르면, 미국에서는 약 1명이 3분마다 혈액암 진단을 받습니다(LLS). 또한 국제암연구소는 2020년에 101만 건의 신규 사례가 진단되었고, 혈액암으로 인한 사망자가 7만 명에 달했다고 추정합니다.

• 의료 인프라에 대한 투자 증가

혈액 악성 종양 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 인프라를 개선하는 데 도움이 되는 의료비 지출 증가입니다. 또한 다양한 정부 기관은 자금을 늘려 의료 인프라를 개선하고자 하며 이는 시장 역학에 더욱 영향을 미칠 것입니다.

• 면역조직화학(IHC)의 발전

Hematologic malignancies can now be accurately detected by exposing tissue samples to diverse antibodies directed against cell molecules and antigens, thanks to developments in immunohistochemistry (IHC). This in turn, estimated to enhance the market's expansion during the forecast period of 2022-2029.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hematologic malignancies market. Additionally, changing lifestyle of people and rising geriatric population will result in the expansion of hematologic malignancies market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hematologic malignancies market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. The advent of new and more efficient diabetic treatment and monitoring products is estimated to boost the market's growth rate in the future. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the hematologic malignancies market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hematologic malignancies market. Additionally, strict regulatory approvals of cancer therapeutics and lack of awareness among people about different types of cancer will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This hematologic malignancies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hematologic malignancies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hematologic malignancies market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hematologic Malignancies Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. The COVID-19 outbreak had touched every element of cancer care and research, as screening and oncology care services were categorized as low-priority services in various nations throughout the world. Furthermore, various local and national-level limitations on the movement of persons and goods imposed by public and private authorities were shown to severely disrupt the pharmaceutical products and ingredients supply chain, hampering the hematologic malignancies market's growth. Also, due to pandemic, the temporary closure of numerous academic institutes and difficulty in delivering post-sales services had resulted in a reduced supply of cancer products to end users.

Recent Development

• In April 2021, U.S. Food and Drug Administration (FDA) had granted orphan drug designation to CA-4948. It is a small-molecular inhibitor that targets an oncogenic isoform of a gene which is mainly expressed in individuals with acute myeloid leukaemia and myelodysplastic syndrome. According to Curis, Inc., Receiving orphan drug classification is a significant step forward in the company's objective to reduce or prevent cancer progression in patients with uncommon hematologic malignancies.
• In February 2021, TG Therapeutics Inc. had announced accelerated approval of U.S. Food and Drug Administration (FDA) for its UKONIQ (umbralisib). It is an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon which is used for treating adult patients suffering from relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL).

Global Hematologic Malignancies Market Scope

The hematologic malignancies market is segmented on the basis of type, therapy, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Leukaemia
• Lymphoma
• Myeloma

Therapy Type

• Chemotherapy
• Immunotherapy
• Targeted Therapy
  • Tyrosine kinase inhibitors
  • Proteasome inhibitor
  • B-cell lymphoma-2 protein inhibitor
  • Isocitrate dehydrogenase-1 inhibitor
  • Hedgehog pathway inhibitor
  • Others

Diagnosis

• Blood Tests
• Biopsy
• Imaging Tests
  •  X-ray
  • Magnetic resonance imaging (MRI)
  • Positron Emission Tomography (PET)
• Others

Dosage form

• Tablets
• Capsules
• Injections
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hematologic Malignancies Market Regional Analysis/Insights

The hematologic malignancies market is analysed and market size insights and trends are provided by country, type, therapy, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Hematologic malignancies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the hematologic malignancies market because of the growing number of research and development activities and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, growing prevalence of blood cancer and rising geriatric population will further influence the market's growth rate in this region

Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and increasing penetration of novel cancer drugs in this region. Also, the development of healthcare infrastructure and increasing disposable income will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hematologic Malignancies Market Share Analysis

혈액암 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 시설 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세 등이 포함됩니다. 위에 제공된 데이터 포인트는 혈액암 시장과 관련된 회사의 초점에만 관련이 있습니다.

혈액암 시장에서 활동하는 주요 기업은 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (아일랜드)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• Bayer AG(독일)
• 엘리 릴리 앤드 컴퍼니(미국)
• 머크앤코(미국)
• 알러간(아일랜드)
• 아스트라제네카(영국)
• AbbVie Inc.(미국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 시플라 주식회사(미국)  
• 애벗(미국)
• 머크 KGaA(독일)
• LEO Pharma A/S(덴마크)
• Bausch Health Companies Inc. (캐나다)
• Sun Pharmaceutical Industries Ltd. (인도)
• Aurobindo Pharma(인도)
• 루팡(인도)
• 히크마 제약(영국)
• Fresenius Kabi AG(독일)
• Amneal Pharmaceuticals LLC. (미국)

SKU-53751